Sugril Adverse Reactions

Endocrine and metabolism disorders: Very common frequency: hypoglycemia, which may be severe and has occasionally been fatal, may occur in patients receiving Glibenclamide.
Symptoms of hypoglycemia include headache, ravenous, hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressive, impaired concentration, alertness and reactions, depression, confusion, difficulty in speaking and even speech loss, visual disorders, tremor, paresis, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsion, somnolence and loss of consciousness up to and including coma, shallow respiration and slow heart rate (bradycardia).
Signs of adrenergic counter-regulation include sweating, clammy skin, anxiety, rapid heart rate (tachycardia), hypertension, palpitations, angina pectoris, and cardiac arrhythmias.
The clinical picture of a severe hypoglycemia attack may resemble that of a stroke. The symptoms nearly always subside when hypoglycemia is corrected.
Common frequency: weight gain.
Unknown frequency: sodium concentration in the serum may decrease.
Eye disorder: Unknown frequency: temporary visual impairment due to the change in blood glucose levels.
Gastrointestinal disorders: Common frequency: nausea, abdominal pain, diarrhea.
Uncommon frequency: sensations of pressure or fullness in the epigastrium.
Unknown frequency: vomiting.
However, despite continued treatment, these often subside and usually do not necessitate discontinuing Glibenclamide.
Hepatobiliary disorders: Unknown frequency: hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice which may progress to life-threatening liver failure but can regress after withdrawal of Glibenclamide.
Blood and lymphatic system disorders: Unknown frequency: mild to severe thrombocytopenia (e.g. presenting as purpura), hemolytic anemia, erythrocytopenia, leukopenia, granulocytopenia, agranulocytosis, pancytopenia.
These reactions are reversible once Glibenclamide has been withdrawn.
Immune system disorders: Unknown frequency: hypersensitivity reactions, allergic or pseudoallergic reactions may occur. Allergy to sulphonamide derivatives may also be responsible for allergic reaction to Glibenclamide. Mild reactions in the form of urticaria may develop into serious and even life-threatening reactions with dyspnea and fall in blood pressure, sometimes progressing to shock.
Skin and subcutaneous disorders: Common frequency: rashes.
Unknown frequency: itching, bullous reactions, erythema multiforme, dermatitis exfoliative, hypersensitivity of skin to light, allergic vasculitis.